Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance of Micro-dose [14C]HSK3486 in Healthy Chinese Males
NCT03751969Phase 1Withdrawn
- Sponsor
- Sichuan Haisco Pharmaceutical Co., Ltd.
- Start
- Mar 2020
- Primary completion
- Nov 2020
- Modality
- Allosteric Modulators
01
Overview
Phase 1, open-label, single-arm trial of ciprofol in general anesthesia and sedation, sponsored by Sichuan Haisco Pharmaceutical Co., Ltd. Primary endpoints: Percentage of cumulative drug excretion of [14C]HSK3486 at 96 hours, Maximum Plasma Concentration [Cmax] at 96 hours and 3 more. Planned start Mar 2020; status: withdrawn.
02
Drugs
ciprofol
03
Conditions
general anesthesiasedation
Beyond the preview
Go deeper on NCT03751969.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03751969.